Literature DB >> 24931199

Constitutively active chemokine CXC receptors.

Xinbing Han1.   

Abstract

Chemokines are low-molecular-weight, secreted proteins that act as leukocyte-specific chemoattractants. The chemokine family has more than 40 members. Based on the position of two conserved cysteines in the N-terminal domain, chemokines can be divided into the CXC, C, CC, and CX3C subfamilies. The interaction of chemokines with their receptors mediates signaling pathways that play critical roles in cell migration, differentiation, and proliferation. The receptors for chemokines are G protein-coupled receptors (GPCRs), and thus far, seven CXC receptors have been cloned and are designated CXCR1-7. Constitutively active GPCRs are present in several human immune-mediated diseases and in tumors, and they have provided valuable information in understanding the molecular mechanism of GPCR activation. Several constitutively active CXC chemokine receptors include the V6.40A and V6.40N mutants of CXCR1; the D3.49V variant of CXCR2; the N3.35A, N3.35S, and T2.56P mutants of CXCR3; the N3.35 mutation of CXCR4; and the naturally occurring KSHV-GPCR. Here, we review the regulation of CXC chemokine receptor signaling, with a particular focus on the constitutive activation of these receptors and the implications in physiological conditions and in pathogenesis. Understanding the mechanisms behind the constitutive activation of CXC chemokine receptors may aid in pharmaceutical design and the screening of inverse agonists and allosteric modulators for the treatment of autoimmune diseases and cancers.
© 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biased signaling; CXC chemokine; Chemokine CXC receptors; Constitutively active mutants; Dimerization; G protein signaling; Inflammation; Inverse antagonist; Small-molecule design; Tumor

Mesh:

Substances:

Year:  2014        PMID: 24931199     DOI: 10.1016/B978-0-12-417197-8.00009-2

Source DB:  PubMed          Journal:  Adv Pharmacol        ISSN: 1054-3589


  11 in total

Review 1.  Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.

Authors:  Catherine J Hutchings; Markus Koglin; William C Olson; Fiona H Marshall
Journal:  Nat Rev Drug Discov       Date:  2017-07-14       Impact factor: 84.694

2.  A substitution in cGMP-dependent protein kinase 1 associated with aortic disease induces an active conformation in the absence of cGMP.

Authors:  Matthew H Chan; Sahar Aminzai; Tingfei Hu; Amatya Taran; Sheng Li; Choel Kim; Renate B Pilz; Darren E Casteel
Journal:  J Biol Chem       Date:  2020-06-05       Impact factor: 5.157

3.  Mesothelial Cell HIF1α Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk.

Authors:  Peter C Hart; Hilary A Kenny; Niklas Grassl; Karen M Watters; Lacey M Litchfield; Fabian Coscia; Ivana Blaženović; Lisa Ploetzky; Oliver Fiehn; Matthias Mann; Ernst Lengyel; Iris L Romero
Journal:  Cell Rep       Date:  2019-12-17       Impact factor: 9.423

4.  Is the 5-hydroxytryptamine 7 Receptor Constitutively Active in the Vasculature? A Study in Veins/Vein.

Authors:  Stephanie W Watts; Emma D Flood; Janice M Thompson
Journal:  J Cardiovasc Pharmacol       Date:  2022-08-01       Impact factor: 3.271

5.  Ligand-Mediated cis-Inhibition of Receptor Signaling in the Self-Incompatibility Response of the Brassicaceae.

Authors:  Titima Tantikanjana; June B Nasrallah
Journal:  Plant Physiol       Date:  2015-08-12       Impact factor: 8.340

6.  Structural biology. Structural basis for chemokine recognition and activation of a viral G protein-coupled receptor.

Authors:  John S Burg; Jessica R Ingram; A J Venkatakrishnan; Kevin M Jude; Abhiram Dukkipati; Evan N Feinberg; Alessandro Angelini; Deepa Waghray; Ron O Dror; Hidde L Ploegh; K Christopher Garcia
Journal:  Science       Date:  2015-03-06       Impact factor: 47.728

7.  3'-Sialyllactose as an inhibitor of p65 phosphorylation ameliorates the progression of experimental rheumatoid arthritis.

Authors:  Li-Jung Kang; Eun-Soo Kwon; Kwang Min Lee; Chanmi Cho; Jae-In Lee; Young Bae Ryu; Tae Hyun Youm; Jimin Jeon; Mi Ra Cho; Seon-Yong Jeong; Sang-Rae Lee; Wook Kim; Siyoung Yang
Journal:  Br J Pharmacol       Date:  2018-10-17       Impact factor: 8.739

8.  CXCR6-based immunotherapy in autoimmune, cancer and inflammatory infliction.

Authors:  Tingting Li; Jie Pan; Hongqi Chen; Yongliang Fang; Yang Sun
Journal:  Acta Pharm Sin B       Date:  2022-03-21       Impact factor: 14.903

9.  Structural basis for chemokine recognition and receptor activation of chemokine receptor CCR5.

Authors:  Hui Zhang; Kun Chen; Qiuxiang Tan; Qiang Shao; Shuo Han; Chenhui Zhang; Cuiying Yi; Xiaojing Chu; Ya Zhu; Yechun Xu; Qiang Zhao; Beili Wu
Journal:  Nat Commun       Date:  2021-07-06       Impact factor: 14.919

10.  Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists.

Authors:  Rama K Mishra; Andrew K Shum; Leonidas C Platanias; Richard J Miller; Gary E Schiltz
Journal:  Sci Rep       Date:  2016-07-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.